MicroPort CRM Raises $150 Million for Implantable CRM Devices

MicroPort Cardiac Rhythm Management closed a $150 million Series C financing including $20 million from Hillhouse and $47 million from MicroPort® Scientific, its parent. MicroPort CRM makes implantable pacemaker and defibrillator devices to manage cardiac rhythm disorders. In 2017, MicroPort acquired the CRM business of Italy's Liva Nova for $190 Million. MicroPort® CRM is headquartered in Clamart, a suburb of Paris, with R&D teams in Clamart and Shanghai. The parent, MicroPort® Scientific, is a global medical device company, headquartered in Shanghai. More details....

Stock Symbol: (HK: 00853)

Share this with colleagues: